SPARK Tel Aviv, Center for Translational Medicine / Chair, Tel Aviv University Cancer Biology Research Center
Dan Peer is a Professor and the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU). He is also the Vice Dean for Research at the George S. Wise Faculty of Life Sciences. From 2016, He is the Chair of Tel Aviv University Cancer Biology Research Center; the biggest Cancer Center in Israel that includes 17 affiliated hospitals and from 2017, the Founding and Managing Director of the SPARK program of Translational Medicine at TAU.
Prof. Peer’s work was among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system and he pioneered the use of RNA interference (RNAi) in immune cells. In addition, his lab was the first to show systemic, cell specific delivery of modified mRNA to cells to induce therapeutic gene expression of desired proteins within the immune system that has enormous implications in cancer and inflammation.
Prof. Peer has more than 100 pending and granted patents. Some of them have been licensed to several pharmaceutical companies and one is currently under registration (as a new drug in inflammatory bowel disease). In addition, based on his work, five spin-off companies were generated aiming to bring innovative personalized medicine into clinical practice.
Prof. Peer is a scientific advisory board member in more than 12 companies, four of them are public companies. He is a past President of the Israeli Chapter of the Controlled Release Society, and a Past Member of the Board of the Israel Young Academy of Science.